• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.真性红细胞增多症后和原发性血小板增多症后骨髓纤维化中细胞遗传学异常的价值：MYSEC项目研究
Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5.
2
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.真性红细胞增多症后和原发性血小板增多症后骨髓纤维化患者的表型和基因型的性别效应：MYSEC项目的结果
Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x.
3
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.真性红细胞增多症、原发性血小板增多症以及原发性骨髓纤维化伴或不伴JAK2 V617F突变时的巨核细胞形态及临床参数
Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.
4
Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis.原发性血小板增多症、真性红细胞增多症和继发性骨髓纤维化的突变模式。
Leuk Lymphoma. 2019 May;60(5):1289-1293. doi: 10.1080/10428194.2018.1522437. Epub 2019 Jan 2.
5
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.一个临床-分子预后模型，用于预测真性红细胞增多症后和特发性血小板增多症后骨髓纤维化患者的生存情况。
Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31.
6
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.原发性骨髓纤维化和真性红细胞增多症后/或原发性血小板增多症后骨髓纤维化患者接受芦可替尼治疗的临床表现、结局和预后模型的差异。一项大型多中心研究中 MYSEC-PM 的新视角。
Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.
7
[Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].[骨髓活检在慢性骨髓增殖性疾病中的预后价值]
Recenti Prog Med. 2003 Jul-Aug;94(7-8):314-20.
8
Prognostication in MF: from CBC to cytogenetics to molecular markers.蕈样肉芽肿的预后评估：从全血细胞计数到细胞遗传学再到分子标志物。
Best Pract Res Clin Haematol. 2014 Jun;27(2):155-64. doi: 10.1016/j.beha.2014.07.008. Epub 2014 Jul 18.
9
Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).慢性骨髓增殖性疾病（MPD）、原发性血小板增多症（ET）、真性红细胞增多症（PV）和慢性特发性骨髓纤维化（CIMF）的现行诊断标准。
Pathol Biol (Paris). 2007 Mar;55(2):92-104. doi: 10.1016/j.patbio.2006.06.002. Epub 2006 Aug 21.
10
A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis.在原发性血小板增多症患者中，血小板中观察到的JAK2 V617F突变克隆比粒细胞中的更高，但真性红细胞增多症和原发性骨髓纤维化患者中并非如此。
Leukemia. 2007 Jun;21(6):1331-2. doi: 10.1038/sj.leu.2404649. Epub 2007 Mar 15.

引用本文的文献

1
Prognostic and Predictive Models in Myelofibrosis.骨髓纤维化的预后和预测模型。
Curr Hematol Malig Rep. 2024 Oct;19(5):223-235. doi: 10.1007/s11899-024-00739-6. Epub 2024 Aug 24.
2
Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision Medicine.真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化的分子认识进展：迈向精准医学
Cancers (Basel). 2024 Apr 26;16(9):1679. doi: 10.3390/cancers16091679.
3
International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms.国际髓系和淋巴肿瘤分类共识：骨髓增殖性肿瘤。
Virchows Arch. 2023 Jan;482(1):53-68. doi: 10.1007/s00428-022-03480-8. Epub 2022 Dec 29.
4
Molecular prognostication in Ph-negative MPNs in 2022.2022 年 Ph 阴性 MPN 中的分子预后。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):225-234. doi: 10.1182/hematology.2022000339.
5
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.迈向个体化定义费城阴性骨髓增殖性肿瘤的预后。
Curr Hematol Malig Rep. 2022 Oct;17(5):127-139. doi: 10.1007/s11899-022-00672-6. Epub 2022 Sep 1.
6
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.预测真性红细胞增多症后和特发性血小板增多症后骨髓纤维化中的血栓形成：一项对 1258 例患者的研究。
Leukemia. 2022 Oct;36(10):2453-2460. doi: 10.1038/s41375-022-01673-3. Epub 2022 Aug 30.
7
Progression in Ph-Chromosome-Negative Myeloproliferative Neoplasms: An Overview on Pathologic Issues and Molecular Determinants.费城染色体阴性骨髓增殖性肿瘤的进展：病理问题与分子决定因素概述
Cancers (Basel). 2021 Nov 4;13(21):5531. doi: 10.3390/cancers13215531.
8
Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.近年来，分子分析在为真性红细胞增多症患者的诊断和预后提供信息方面的应用进展。
Int J Mol Sci. 2021 May 10;22(9):5042. doi: 10.3390/ijms22095042.
9
Is there a gender effect in polycythemia vera?真性红细胞增多症中存在性别效应吗？
Ann Hematol. 2021 Jan;100(1):11-25. doi: 10.1007/s00277-020-04287-w. Epub 2020 Oct 2.
10
Standard care and investigational drugs in the treatment of myelofibrosis.骨髓纤维化治疗中的标准护理与研究性药物。
Drugs Context. 2019 Sep 26;8:212603. doi: 10.7573/dic.212603. eCollection 2019.

本文引用的文献

1
Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis.当前原发性骨髓纤维化预后模型在真性红细胞增多症后或原发性血小板增多症后骨髓纤维化中的应用。
Leukemia. 2017 Dec;31(12):2851-2852. doi: 10.1038/leu.2017.268. Epub 2017 Aug 18.
2
Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance.世界卫生组织定义的真性红细胞增多症的细胞遗传学发现及其预后相关性。
Br J Haematol. 2018 Aug;182(3):437-440. doi: 10.1111/bjh.14798. Epub 2017 Jun 9.
3
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.原发性血小板增多症后和真性红细胞增多症后的患者与原发性骨髓纤维化患者有所不同。
Leuk Res. 2017 Aug;59:110-116. doi: 10.1016/j.leukres.2017.06.001. Epub 2017 Jun 2.
4
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.一个临床-分子预后模型，用于预测真性红细胞增多症后和特发性血小板增多症后骨髓纤维化患者的生存情况。
Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31.
5
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera.原发性骨髓纤维化中细胞遗传学异常的特征和临床意义。
Haematologica. 2017 Sep;102(9):1511-1518. doi: 10.3324/haematol.2017.165795. Epub 2017 May 4.
6
Update from the latest WHO classification of MPNs: a user's manual.世界卫生组织髓系增殖性肿瘤最新分类更新：用户指南。
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):534-542. doi: 10.1182/asheducation-2016.1.534.
7
Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.驱动突变在继发性骨髓纤维化中的作用：一项基于781例患者的国际多中心研究。
Leukemia. 2017 Apr;31(4):970-973. doi: 10.1038/leu.2016.351. Epub 2016 Nov 25.
8
A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients.骨髓纤维化细胞遗传学异常简编：826例患者的分子与表型相关性
Br J Haematol. 2015 Apr;169(1):71-6. doi: 10.1111/bjh.13260. Epub 2014 Dec 17.
9
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.原发性骨髓纤维化在真性红细胞增多症中产生影响。
Blood. 2012 Mar 8;119(10):2239-41. doi: 10.1182/blood-2011-11-393819. Epub 2012 Jan 13.
10
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.JAK2 GGCC 单倍型和 TET2 基因在家族性骨髓增殖性肿瘤中的作用。
Haematologica. 2011 Mar;96(3):367-74. doi: 10.3324/haematol.2010.034488. Epub 2010 Dec 20.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

作者信息

Mora Barbara, Giorgino Toni, Guglielmelli Paola, Rumi Elisa, Maffioli Margherita, Rambaldi Alessandro, Caramella Marianna, Komrokji Rami, Gotlib Jason, Kiladjian Jean Jacques, Cervantes Francisco, Devos Timothy, Palandri Francesca, De Stefano Valerio, Ruggeri Marco, Silver Richard T, Benevolo Giulia, Albano Francesco, Cavalloni Chiara, Barraco Daniela, Merli Michele, Pietra Daniela, Casalone Rosario, Barbui Tiziano, Rotunno Giada, Cazzola Mario, Vannucchi Alessandro Maria, Passamonti Francesco

机构信息

Hematology, Department of Medicine and Surgery, University of Insubria, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy.

Biophysics Institute, National Research Council of Italy, Milano, Italy.

出版信息

Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5.

DOI:10.3324/haematol.2017.185751
PMID:
29622658
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6119135/
Abstract
摘要